While Surriga et al. [33] suggested that Crizotinib could be used in adjuvant therapy for uveal melanoma due to its c-Met activity inhibition, recent research reported strong kinase fusion association with different melanoma subtypes [35] and encouraged the testing of kinase fusion inhibitor Crizotinib for melanoma treatment [34]. The gene discussed is MET; the disease is melanoma.